C-RAD AB: First orders and installations of the Catalyst system
Press release 2011-10-17
First orders and installations of the C-RAD Catalyst™ system
C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. The superior solution for free breathing gating with the new Catalyst™ system and retrospective gating on the CT with the Sentinel™ system have resulted in first orders and installations of systems in Europe, USA and East Asia.
With the introduction of the Catalyst™ system C-RAD has launched a unique solution for free breathing gating. Together with the Sentinel™ system for gated computed tomography a solution with superior performance can be offered to the radiation therapy clinics.
The Catalyst™ system can in parallel control the respiratory gating process and monitor overall patient motion during treatment delivery. The system can without accessories monitor both thoracic and abdominal respiration with sub-millimeter accuracy. These capabilities provide greatly increased patient safety as well as confidence in the stability of each patient’s individual breathing pattern, thereby enabling higher doses to be delivered to the intended target with minimal exposure to healthy tissue.
The first systems were installed and validated at the Skåne University Hospital in Malmö, Sweden. After successful completion of the validation activities and official market release on 30 September 2011, more installations will in the next few weeks follow in Germany, Sweden, South Korea, USA etc.
The new Catalyst™ system and the previously launched Sentinel™ system form a complete product offering and tailored configurations can be offered based on customer requests. With this product portfolio is C-RAD the world leading company to offer optical surface tracking and monitoring systems for enhanced precision, patient safety and efficiency in advanced radiation therapy.
Erik Hedlund, CEO, C-RAD AB:
"During last two years C-RAD has experienced a fast growing demand for systems with respiratory gating both with free breathing and breath hold. The objective is to reduce dose to the cardiac tissue. C-RAD can for the first time deliver a superior system for this application based on Catalyst and Sentinel. The immediate response by larger clinics is encouraging. Important is also the availability of interfaces to Varian linacs."
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.se